<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246129</url>
  </required_header>
  <id_info>
    <org_study_id>SMHREN0501</org_study_id>
    <secondary_id>2005-002856-17</secondary_id>
    <nct_id>NCT00246129</nct_id>
  </id_info>
  <brief_title>CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation</brief_title>
  <official_title>A Randomised Controlled Comparison of Campath-Tacrolimus vs IL2R MoAb-Tacrolimus/Mycophenolate Mofetil in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMagnusson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The advent of new, potent immunosuppressive (anti-rejection) drugs over the past ten years&#xD;
      has substantially reduced the risk of rejection after kidney transplantation, has allowed the&#xD;
      development of immuno-suppressive regimens that do not use long-term steroids (steroid&#xD;
      avoidance), and has improved transplant success rates both in the short and medium term.&#xD;
&#xD;
      The main new agents used in these modern regimens are the calcineurin inhibitor (CNI)&#xD;
      tacrolimus; the anti-proliferative agent mycophenolate; and induction agents which are used&#xD;
      to provide effective early suppression of the rejection process; these include monoclonal&#xD;
      antibodies (MoAb) such as IL-2 receptor blocking antibodies (IL-2R MoAb: basiliximab and&#xD;
      daclizumab) and the anti-CD52 antibody Campath-1H (alemtuzumab).&#xD;
&#xD;
      Although almost all modern immunosuppressive regimens involve one or more of these agents, it&#xD;
      is not known which is the safest and most effective combination.&#xD;
&#xD;
      This randomised controlled trial compares two steroid sparing regimens which have been used&#xD;
      with very good short and medium term results at St Mary's Hospital Renal and Transplant Unit&#xD;
      over the last 5 years. The primary hypothesis is that the alemtuzumab/tacrolimus regimen is&#xD;
      as effective and safe as the IL-2R MoAb/tacrolimus/mycophenolate regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RECENT EXPERIENCE AT ST MARY'S:&#xD;
&#xD;
      The St Mary's Hospital Renal Unit (now combined with the Hammersmith Hospital Renal Unit at&#xD;
      the West London Renal and Transplant Centre) introduced Tacrolimus based immunosuppression in&#xD;
      1995, developing a steroid avoidance regimen based on Tacrolimus, Mycophenolate, and IL-2R&#xD;
      MoAb between 2000 and 2002, and moving to Campath-1H as an induction agent in 2004. Results&#xD;
      over this period have been excellent with five and ten year survivals with functioning graft&#xD;
      rates of 82% and 72% for the first 260 cadaveric kidney transplants performed since 1995.&#xD;
&#xD;
      The two most recent regimens used at St Mary's have both produced very low (&lt; 10%) rejection&#xD;
      rates, and very good (&gt; 90%) short-term rejection-free patient and graft survival rates.&#xD;
      Between 2002 and 2004, the regimen consisted of induction with an Interleukin-2 (IL2)&#xD;
      -Receptor blocking monoclonal antibody with Tacrolimus and Mycophenolate as long term&#xD;
      maintenance therapy. In patients without rejection steroid usage was limited to the first 7&#xD;
      days post-transplant. The current regimen uses Campath-1H (which is now well established as&#xD;
      an induction agent in renal transplantation for induction), with Tacrolimus monotherapy&#xD;
      maintenance and an identical short-course steroid regimen.&#xD;
&#xD;
      CHARACTERISTICS OF THE TWO REGIMENS TO BE COMPARED:&#xD;
&#xD;
      The IL2R MoAb/Tacrolimus/Mycophenolate/Short-course steroids regimen (2002-2004 Regimen 1)&#xD;
      has the advantage of flexibility in terms of adjusting maintenance therapy to allow clinical&#xD;
      response to patients and transplants with different tolerance of the two maintenance agents,&#xD;
      but involves increased expense in terms of using and monitoring the blood levels of two&#xD;
      modern (and hence expensive) agents. In addition, patients have long-term exposure to the&#xD;
      anti-proliferative agent Mycophenolate, which can be associated with increased risk of&#xD;
      infection, gastrointestinal side effects, and skin malignancies.&#xD;
&#xD;
      The Campath-1H/Tacrolimus/Short-course steroids regimen (2004-current, Regimen 2) has the&#xD;
      advantage of highly effective immunosuppression in the initial 3-month period, allowing lower&#xD;
      doses of the potentially nephrotoxic Tacrolimus to be used, and simplicity, but exposes&#xD;
      patients to a period of several months of lymphopenia (reduced lymphocyte counts in the&#xD;
      blood) after Campath administration, and reliance on Tacrolimus monotherapy for maintenance&#xD;
      which might lead to greater long term Tacrolimus exposure.&#xD;
&#xD;
      PROPOSED STUDY:&#xD;
&#xD;
      In order to allow a proper comparison of these two anti-rejection treatment combinations we&#xD;
      propose a randomised trial which will enable us to consider the relative merits of the two&#xD;
      regimens without the introduction of bias associated with using historical control groups.&#xD;
      Transplant recipients will be randomised in a 1:2 ratio to regimen 1 and regimen 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One Year Survival With a Functioning Graft</measure>
    <time_frame>1 year</time_frame>
    <description>One year survival with a functioning graft, defined as transplant recipient remaining alive and dialysis-independent. the functioning graft is a graft still functioning at the time of analysis.&#xD;
Graft function was estimated using the Modification of Diet in Renal Disease four-variable formula and comparison of graft function between arms undertaken with Student'st test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Rejection Episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Biopsy-proven rejection episodes classified using Banff criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Significant Episodes of Infection</measure>
    <time_frame>1 year</time_frame>
    <description>Occurence of infection of sufficient severity to produce positive cultures or Nucleic-acid test results from blood, urine, or other body fluids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Length of Stay in Hospital</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence in the Blood of Cells Which Might Trigger Rejection in, or Promote Tolerance to the Graft</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Development of Scarring in the Grafts</measure>
    <time_frame>1 year</time_frame>
    <description>Biopsy proven Calcineurin Inhibitor (CNI) toxicity free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Function: Level of Creatinine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival Censored for Death With Function</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival Censored for Death With Function</measure>
    <time_frame>2 years</time_frame>
    <description>Graft survival (defined as grafts maintaining dialysis independence)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Kidney Diseases</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Campath-Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclizumab-Tacrolimus-Mycophenolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Monoclonal antibody induction therapy</description>
    <arm_group_label>Campath-Tacrolimus</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>Monoclonal antibody induction therapy</description>
    <arm_group_label>Daclizumab-Tacrolimus-Mycophenolate</arm_group_label>
    <other_name>Zinbryta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant recipients under the care of the West London Renal and Transplant&#xD;
             Centre&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to give written informed consent&#xD;
&#xD;
          -  Simultaneous kidney/pancreas transplant recipients&#xD;
&#xD;
          -  Non-heart beating deceased donor transplant recipients&#xD;
&#xD;
          -  Patients who would not be offered Campath-1H induction under our current protocol&#xD;
             (patients with previous malignancy or with previous exposure to cytotoxic or&#xD;
             antiproliferative agents)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam G McLean, FRCP, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David H Taube, MBBCh, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Hammersmith Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West London Renal and Transplant Centre, 4th Floor Ham House, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Loucaidou M, McLean AG, Cairns TD, Griffith M, Hakim N, Palmer A, Papalois V, Van Tromp J, Loucaides C, Welsh KI, Taube D. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting significance of vascular rejection. Transplantation. 2003 Oct 15;76(7):1120-3.</citation>
    <PMID>14557763</PMID>
  </reference>
  <reference>
    <citation>Borrows R, Loucaidou M, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant. 2004 Nov;4(11):1845-51.</citation>
    <PMID>15476485</PMID>
  </reference>
  <reference>
    <citation>Borrows R, Loucaidou M, Van Tromp J, Singh S, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results. Transplant Proc. 2005 May;37(4):1792-4.</citation>
    <PMID>15919468</PMID>
  </reference>
  <results_reference>
    <citation>Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca.</citation>
    <PMID>21836540</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2005</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>September 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College Healthcare NHS Trust</investigator_affiliation>
    <investigator_full_name>EMagnusson</investigator_full_name>
    <investigator_title>RIO</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Kidney Disease</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>Graft Rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Campath-Tacrolimus</title>
          <description>Campath (1x30mg) induction with 7-day short-course steroids followed by tacrolimus monotherapy (dose adjusted to target trough level 9-11ng/ml)</description>
        </group>
        <group group_id="P2">
          <title>Daclizumab-Tacrolimus-Mycophenolate</title>
          <description>Daclizumab 2mg/kg x2 days 0+14) induction with 7-day short-course steroids followed by Tacrolimus (adjusted to target trough 9-11ng/ml) and Mycophenolate mofetil therapy (750mg bd)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>suffered primary non-function</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>grafts failed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Campath-Tacrolimus</title>
          <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
        </group>
        <group group_id="B2">
          <title>Daclizumab-Tacrolimus-Mycophenolate</title>
          <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="13.4"/>
                    <measurement group_id="B2" value="47.0" spread="10.6"/>
                    <measurement group_id="B3" value="47.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>One Year Survival With a Functioning Graft</title>
        <description>One year survival with a functioning graft, defined as transplant recipient remaining alive and dialysis-independent. the functioning graft is a graft still functioning at the time of analysis.&#xD;
Graft function was estimated using the Modification of Diet in Renal Disease four-variable formula and comparison of graft function between arms undertaken with Student'st test.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Survival With a Functioning Graft</title>
          <description>One year survival with a functioning graft, defined as transplant recipient remaining alive and dialysis-independent. the functioning graft is a graft still functioning at the time of analysis.&#xD;
Graft function was estimated using the Modification of Diet in Renal Disease four-variable formula and comparison of graft function between arms undertaken with Student'st test.</description>
          <units>Percent of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="90.6" upper_limit="99.4"/>
                    <measurement group_id="O2" value="95.1" lower_limit="81.9" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Rejection Episodes</title>
        <description>Biopsy-proven rejection episodes classified using Banff criteria</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath Tacrolimus</title>
            <description>Alemtuzumab induction with short-course steroids and Tacrolimus maintenance monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Rejection Episodes</title>
          <description>Biopsy-proven rejection episodes classified using Banff criteria</description>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="82.4" upper_limit="95.7"/>
                    <measurement group_id="O2" value="82.3" lower_limit="66.4" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.138</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Significant Episodes of Infection</title>
        <description>Occurence of infection of sufficient severity to produce positive cultures or Nucleic-acid test results from blood, urine, or other body fluids</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Significant Episodes of Infection</title>
          <description>Occurence of infection of sufficient severity to produce positive cultures or Nucleic-acid test results from blood, urine, or other body fluids</description>
          <units># of occurrences per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Length of Stay in Hospital</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Length of Stay in Hospital</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="6.4"/>
                    <measurement group_id="O2" value="12.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence in the Blood of Cells Which Might Trigger Rejection in, or Promote Tolerance to the Graft</title>
        <time_frame>3 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Campath Tacrolimus '</title>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
          </group>
        </group_list>
        <measure>
          <title>Presence in the Blood of Cells Which Might Trigger Rejection in, or Promote Tolerance to the Graft</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Development of Scarring in the Grafts</title>
        <description>Biopsy proven Calcineurin Inhibitor (CNI) toxicity free survival</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Early Development of Scarring in the Grafts</title>
          <description>Biopsy proven Calcineurin Inhibitor (CNI) toxicity free survival</description>
          <units>Percentage of participants with no scar</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Function: Level of Creatinine</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Function: Level of Creatinine</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.3" spread="36.2"/>
                    <measurement group_id="O2" value="147.0" spread="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival Censored for Death With Function</title>
        <description>Cumulative patient survival</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival Censored for Death With Function</title>
          <description>Cumulative patient survival</description>
          <units>Percentage of transplant recipients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival Censored for Death With Function</title>
        <description>Graft survival (defined as grafts maintaining dialysis independence)</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campath-Tacrolimus</title>
            <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Daclizumab-Tacrolimus-Mycophenolate</title>
            <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival Censored for Death With Function</title>
          <description>Graft survival (defined as grafts maintaining dialysis independence)</description>
          <units>Percentage of grafts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Campath-Tacrolimus</title>
          <description>Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy</description>
        </group>
        <group group_id="E2">
          <title>Daclizumab-Tacrolimus-Mycophenolate</title>
          <description>Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <description>ITP</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>New-onset diabetes after transplantation</sub_title>
                <description>NODAT</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Other infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our trial was conservatively powered to detect a large difference in survival with a functioning graft at 1 year, so we are not able to exclude the possibility of small differences, the single-centre nature of the study may limit it's applicability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Adam McLean</name_or_title>
      <organization>imperial College Kidney &amp; Transplant Centre</organization>
      <phone>+44 (0) 208 383 5164 ext 356164</phone>
      <email>adam.mclean@imperial.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

